

Richard Morphy



After completing his Ph.D. at Durham University (U.K.), Richard Morphy joined Celltech Ltd. (later UCB) in Slough (U.K.) as a medicinal chemist working on a variety of oncology and inflammation projects. Subsequently he moved to Organon Laboratories in Scotland where he was a section head in the medicinal chemistry department until 2011, through the mergers of Organon with Schering-Plough in 2007 and Merck in 2009. His primary focus there was on CNS disorders and this led to a keen interest and expertise in the field of multi-target drug discovery. Three years ago, he moved to the Lilly Research Centre in Windlesham, Surrey, UK with a continued focus on the neuroscience disease area.